--- title: "MonotaRO Stock And Two High Quality Undervalued Compounders To Watch" type: "News" locale: "en" url: "https://longbridge.com/en/news/289992324.md" description: "The article highlights three undervalued high-quality stocks: MonotaRO, Round One, and Chugai Pharmaceutical. MonotaRO, an MRO supplier, offers strong ROE but faces borrowing risks. Round One, a leisure complex operator, shows efficient profitability despite lagging share performance and external debt. Chugai Pharmaceutical boasts high margins and ROE in the biotech sector, though it relies heavily on key drugs and Roche partnerships. All three are screened for healthy cash flows and balance sheets trading below estimated fair value." datetime: "2026-06-17T03:09:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/289992324.md) - [en](https://longbridge.com/en/news/289992324.md) - [zh-HK](https://longbridge.com/zh-HK/news/289992324.md) generator: "portal-rs" --- # MonotaRO Stock And Two High Quality Undervalued Compounders To Watch With inflation, interest rates and growth signals pulling markets in different directions, many investors are looking for solid companies that still trade at sensible prices. That is where the High Quality Undervalued Stocks screener comes in. It focuses on businesses with healthy cash flows and balance sheets that the market has not fully recognised. In the following sections, the article highlights 3 of the best stocks from this screener, explaining why each one stands out, how it fits this quality plus value theme, and what type of investor might find each stock worth a closer look. ## MonotaRO (TSE:3064) **Overview:** MonotaRO is an online supplier of maintenance, repair and operations products, providing everything from safety gear and tools to office, automotive and medical supplies to factories and businesses in Japan and overseas, and operates as a subsidiary of Grainger Global Holdings. **Operations:** MonotaRO generates all of its ¥350,356m revenue from indirect material sales to factories, with the full amount reported in Japan. **Market Cap:** ¥855.6b MonotaRO stock appears in this screener because it combines a large, focused MRO marketplace with profitability and growth, while trading below an estimated value of its future cash flows. Earnings growth has been strong in recent years and margins are described as healthy, supported by an asset light online model and a Return on Equity of 28.9%. At the same time, the company’s reliance on higher risk external borrowing and a dividend that is not well covered by free cash flow are highlighted as important pressure points for long term investors. Recent share buybacks also affect the picture for capital allocation, which makes the fuller investment case more complex than a quick glance at the P/E might suggest. MonotaRO’s high Return on Equity and asset-light model suggest a powerful earnings engine, but the real story sits inside the 4 key rewards and 1 important warning sign, where its borrowing and dividend coverage raise one big question 3064 Discounted Cash Flow as at Jun 2026 ## Round One (TSE:4680) **Overview:** Round One operates large indoor leisure complexes that combine bowling, arcade games, karaoke, billiards and its Spo-Cha multi-sport facilities. This provides multiple revenue streams from family entertainment and social outings across Japan and overseas. **Operations:** Round One generates most of its revenue from Japan at ¥108,689m, with sizeable contribution from the United States at ¥79,662m and a smaller amount from other regions at ¥1,196m. **Market Cap:** ¥268.5b Round One stock appears on this quality plus value screen because it pairs a broad entertainment offering with current profitability metrics and a valuation that sits well below an internal estimate of fair value. The company reports net profit margins close to 9%, supported by a Return on Equity of around 20%, which indicates the existing leisure footprint is being used efficiently. At the same time, all liabilities come from higher risk external borrowing and the share price has lagged the wider Japanese market over the past year, so investors need to weigh funding risk and sentiment carefully against the earnings quality profile. Round One’s 9% net margins and around 20% Return on Equity hint at an underrated entertainment engine, yet the share price has lagged and all liabilities sit in higher risk borrowing, making the analysis report for Round One feel like the missing twist in the story. 4680 Discounted Cash Flow as at Jun 2026 ## Chugai Pharmaceutical (TSE:4519) **Overview:** Chugai Pharmaceutical is a research driven drug company that develops, manufactures and sells prescription medicines for cancer, autoimmune conditions, viral infections and rare diseases, leveraging its partnership with Roche to distribute a portfolio of biologic therapies such as Hemlibra, Actemra and Avastin in Japan and overseas. **Operations:** Chugai Pharmaceutical generates all of its ¥1,291,229m revenue from pharmaceuticals, with reported sales across Japan at ¥482,036m and Switzerland at ¥771,217m, alongside a segment adjustment of ¥786,567m. **Market Cap:** ¥12,381.1b Chugai Pharmaceutical catches the eye because it combines high current profitability, with net margins around 35% and a Return on Equity near 24%, with a drug portfolio that sits in the centre of demand for complex biologics in cancer and autoimmune disease. The stock is described as trading below an internal cash flow based estimate of fair value, even though the P/E is higher than many peers. The flip side is heavy dependence on a handful of blockbuster drugs and close reliance on Roche, so the key question is how the pipeline and partnership risks compare with that earnings profile and valuation. Chugai Pharmaceutical’s high margins and 24% Return on Equity hint at a powerful engine, yet reliance on a few blockbuster drugs and Roche leaves a crucial question hanging in the 4 key rewards and 1 important warning sign 4519 Discounted Cash Flow as at Jun 2026 The three stocks highlighted here are just a starting point. The full High Quality Undervalued Stocks screener surfaces 15 more companies that pair solid balance sheets and strong cash flows with equally compelling stories. To identify and analyze the highest conviction ideas for yourself, use Simply Wall St to filter the specific catalysts and narratives behind the High Quality Undervalued Stocks screener. ## Take Control of Your Investment Journey If Chugai Pharmaceutical or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market. ## Seeking Fresh Alternatives Beyond Today’s Picks Markets move fast and the most interesting ideas often gain momentum quietly before anyone notices. Scan these fresh stock lists while the data is still under the radar for now and consider them while they remain less widely followed. - Spot rising cash generators early by scanning the curated 57 high quality undiscovered gems that pair strong balance sheets with business models many investors have not fully evaluated yet. - Target income sources with staying power by reviewing the hand picked 53 dividend fortresses built around companies aiming to combine yield with sturdier fundamentals. - Track infrastructure behind tomorrow’s computing breakthroughs by using the focused 48 AI infrastructure stocks featuring businesses supplying the tools and backbone for growing AI demand. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [4519.JP](https://longbridge.com/en/quote/4519.JP.md) - [3064.JP](https://longbridge.com/en/quote/3064.JP.md) - [4680.JP](https://longbridge.com/en/quote/4680.JP.md) - [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md) - [GWW.US](https://longbridge.com/en/quote/GWW.US.md) - [CHGCY.US](https://longbridge.com/en/quote/CHGCY.US.md) - [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md) ## Related News & Research - [MonotaRO Extends Double-Digit Sales Growth With Strong August Results](https://longbridge.com/en/news/298549876.md) - [Roche announces MediLink’s phase III trial of Tam-Peli met primary endpoint](https://longbridge.com/en/news/298840024.md) - [How Investors Are Reacting To Round One (TSE:4680) Monthly Sales Update](https://longbridge.com/en/news/298945412.md) - [IDYA: Darovasertib NDA nears completion as pipeline expands with DLL3 ADC, PRMT5, and Roche collaborations](https://longbridge.com/en/news/298488281.md) - [Lindbergh Updates Shareholding Structure as CEO’s Holding Dips Below 25%](https://longbridge.com/en/news/298593976.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**